Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

Tesamorelin 10mg

Tesamorelin 10mg

$71.00

Tesamorelin 10mg is a synthetic growth hormone-releasing hormone (GHRH) analogue peptide designed to stimulate the natural release of growth hormone (GH) from the pituitary gland. By mimicking the action of endogenous GHRH, Tesamorelin promotes GH secretion in a physiological pattern, supporting research into metabolism, muscle growth, and fat regulation. This peptide is a stable, high-purity formulation ideal for scientific and laboratory research. Unlike direct HGH injections, Tesamorelin works indirectly encouraging the body’s own GH production rhythm rather than suppressing it.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C₂₂₁H₃₆₆N₇₂O₆₇S
CAS Number 218949-48-5
Molar Mass 5135.86 g/mol
Amino Acid Sequence Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH)
PubChem CID 146681838
Primary Research Area Reduce Visceral Adipose Tissue (VAT) in HIV-infected patients with lipodystrophy
Insulin Resistance
Obesity
Nonalcoholic Fatty Liver Disease (NAFLD)
GHRH Receptor Agonist
Stimulate GH/IGF-1
Improve Metabolic Profile
Improve Fat Quality
Research Summary Description
Tesamorelin improves fat quality independent of changes in fat quantity Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH).

Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213.
The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue).

Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173.
Effects of Tesamorelin on nonalcoholic fatty liver disease in HIV: A randomized, double-blind, multicenter trial Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups.

Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5.

Tesamorelin improves fat quality independent of changes in fat quantity

Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH).

Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213.

The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV

Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue).

Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173.

Effects of Tesamorelin on nonalcoholic fatty liver disease in HIV: A randomized, double-blind, multicenter trial

Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups.

Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping